|
KRBA2 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 5.50089995776659E-09 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
3.2435999997027E-07 |
| Normal-vs-Stage2 |
7.563000E-03 |
| Normal-vs-Stage3 |
5.0760999958932E-08 |
| Normal-vs-Stage4 |
1.96640004279658E-09 |
| Stage1-vs-Stage2 |
1.549000E-01 |
| Stage1-vs-Stage3 |
2.684000E-01 |
| Stage1-vs-Stage4 |
5.023900E-03 |
| Stage2-vs-Stage3 |
3.364200E-02 |
| Stage2-vs-Stage4 |
1.763890E-03 |
| Stage3-vs-Stage4 |
1.303820E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
5.63019997290581E-09 |
| Normal-vs-AfricanAmerican |
3.956800E-03 |
| Normal-vs-Asian |
2.019600E-04 |
| Caucasian-vs-AfricanAmerican |
5.098800E-01 |
| Caucasian-vs-Asian |
9.236000E-01 |
| AfricanAmerican-vs-Asian |
6.502200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
4.02860000026095E-07 |
| Normal-vs-Female |
1.32140000053127E-08 |
| Male-vs-Female |
7.443800E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.70139999977614E-07 |
| Normal-vs-Age(41-60Yrs) |
1.189199999585E-07 |
| Normal-vs-Age(61-80Yrs) |
4.50659999995384E-06 |
| Normal-vs-Age(81-100Yrs) |
1.490310E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
8.004800E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
9.384400E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
6.751600E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
7.740400E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
7.469800E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
6.768400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.989170E-04 |
| Classical-VS-Follicular |
8.427600E-01 |
| Classical-VS-Other |
8.724200E-01 |
| Classical-VS-Normal |
1.58970000052605E-07 |
| Tall-VS-Follicular |
4.022100E-03 |
| Tall-VS-Other |
3.543800E-01 |
| Tall-VS-Normal |
5.82179970898267E-10 |
| Follicular-VS-Other |
9.355600E-01 |
| Follicular-VS-Normal |
4.21860000000551E-05 |
| Other-VS-Normal |
5.274200E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
9.43460000013552E-07 |
| Normal-vs-N1 |
5.69489999602268E-08 |
| N0-vs-N1 |
7.006400E-02 |
|
|
